Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-07-10 8:34 pm Unchanged | 13G | Acrivon Therapeutics Inc. ACRV | Chione Ltd | 3,848,632 12.500% | 0 (Unchanged) | View |
| 2024-07-10 8:29 pm Sale | 13G | Acrivon Therapeutics Inc. ACRV | Chione Ltd | 3,848,632 17.300% | -7,965 (-0.21%) | View |
| 2024-04-15 08:21 am Purchase | 13G | Acrivon Therapeutics Inc. ACRV | PERCEPTIVE ADVISORS LLC | 5,360,858 17.400% | 2,353,000 (+78.23%) | View |
| 2024-04-11 4:16 pm Purchase | 13D | Acrivon Therapeutics Inc. ACRV | RA CAPITAL MANAGEMENT L.P. | 8,359,102 27.100% | 3,541,743 (+73.52%) | View |
| 2024-02-14 4:57 pm Purchase | 13G | Acrivon Therapeutics Inc. ACRV | CITADEL ADVISORS LLC | 1,649,664 7.400% | 15,515 (+0.95%) | View |
| 2024-02-14 4:36 pm Unchanged | 13G | Acrivon Therapeutics Inc. ACRV | PERCEPTIVE ADVISORS LLC | 3,007,858 13.600% | 0 (Unchanged) | View |
| 2024-02-14 09:51 am Sale | 13G | Acrivon Therapeutics Inc. ACRV | Marshall Wace North America L.P. | 597,469 2.700% | -625,783 (-51.16%) | View |
| 2024-02-13 3:40 pm Sale | 13G | Acrivon Therapeutics Inc. ACRV | Sands Capital Ventures LLC | 1,652,605 7.400% | -1 (-0.00%) | View |
| 2023-03-30 5:07 pm Purchase | 13D | Acrivon Therapeutics Inc. ACRV | RA CAPITAL MANAGEMENT L.P. | 4,817,359 22.000% | 3,917 (+0.08%) | View |
| 2023-02-14 3:26 pm Purchase | 13G | Acrivon Therapeutics Inc. ACRV | Sands Capital Ventures LLC | 1,652,606 7.900% | 1,652,606 (New Position) | View |
| 2023-02-14 2:33 pm Unchanged | 13G | Acrivon Therapeutics Inc. ACRV | PERCEPTIVE ADVISORS LLC | 3,007,858 14.400% | 0 (Unchanged) | View |
| 2023-02-14 09:35 am Purchase | 13G | Acrivon Therapeutics Inc. ACRV | Marshall Wace North America L.P. | 1,223,252 5.900% | 1,223,252 (New Position) | View |
| 2023-02-14 08:02 am Sale | 13G | Acrivon Therapeutics Inc. ACRV | CITADEL ADVISORS LLC | 1,634,149 7.800% | -488 (-0.03%) | View |
| 2022-11-28 4:31 pm Purchase | 13D | Acrivon Therapeutics Inc. ACRV | RA CAPITAL MANAGEMENT L.P. | 4,813,442 23.070% | 4,813,442 (New Position) | View |
| 2022-11-28 3:59 pm Purchase | 13G | Acrivon Therapeutics Inc. ACRV | Chione Ltd | 3,856,597 18.500% | 3,856,597 (New Position) | View |
| 2022-11-25 4:25 pm Purchase | 13G | Acrivon Therapeutics Inc. ACRV | Sands Capital Life Sciences Pulse Fund II L.P. | 1,652,606 7.900% | 1,652,606 (New Position) | View |
| 2022-11-21 4:01 pm Purchase | 13G | Acrivon Therapeutics Inc. ACRV | CITADEL ADVISORS LLC | 1,634,637 7.800% | 1,634,637 (New Position) | View |
| 2022-11-18 4:31 pm Purchase | 13G | Acrivon Therapeutics Inc. ACRV | PERCEPTIVE ADVISORS LLC | 3,007,858 14.400% | 3,007,858 (New Position) | View |